Evidence map›Paper›PMID 41836423›Full record

ReviewFrontiers in immunology2026

Research progress on the lectin pathway of complement in IgA nephropathy.

Xiaoqing Yu, Hui Gao, Xifeng Sun

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Xiaoqing Yu *The Second Clinical Medical College of Binzhou Medical University, Yantai, China.
Hui Gao *Department of Urology, Zibo Central Hospital., Zibo, China.
Xifeng SunDepartment of Nephrology, Zibo Central Hospital, Zibo, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As an autoimmune disease, IgA nephropathy is pathologically characterized by the deposition of immunoglobulin A (IgA) in the glomerular mesangial area. Recent research has confirmed that the activation of the lectin pathway in the complement system may be related to the development and prognosis of IgA nephropathy (IgAN). These deposited immune complexes trigger the complement cascade, generating various inflammatory mediators that directly attack glomerular mesangial cells and promote mesangial matrix proliferation and crescent formation, ultimately leading to end stage renal disease. Therefore, an in-depth understanding of complement activation pathways not only provides potential non-invasive biomarkers (such as urinary complement components) for assessing disease activity and prognosis, more importantly, establishes a theoretical foundation for developing novel anti-complement targeted therapies. This holds promise for opening new directions in the personalized precision treatment of IgA nephropathy. This article reviews the research progress on the lectin pathway and its associated components in IgA nephropathy.

Indexed as

Complement Pathway, Mannose-Binding LectinComplement System ProteinsGlomerulonephritis, IGALectinsAnimalsBiomarkersComplement ActivationHumansImmunoglobulin ABiomarkersComplement System ProteinsImmunoglobulin ALectinsC4dcomplement systemcrescentIgA nephropathy (IgAN)lectin pathway (MBL)MASP

Identifiers

PMID41836423
PMCPMC12982443

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.